Please login to the form below

Not currently logged in
Email:
Password:

Darzalex

This page shows the latest Darzalex news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices

Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices. ... Image credit: Trump Baby UK. NICE says no to myeloma ‘game changer’Darzalex.

Latest news

  • J&J moves quickly ahead with trials of myeloma CAR-T J&J moves quickly ahead with trials of myeloma CAR-T

    Meanwhile, hopes that its anti-CD38 Darzalex (daratumumab) could find a role alongside checkpoint inhibitors in blood cancers and solid tumours took a knock earlier this week after safety issues led

  • Safety scuppers combo trials with J&J/Genmab’s Darzalex Safety scuppers combo trials with J&J/Genmab’s Darzalex

    trial, according to Genmab that prompted J&J - Genmab’s partner for Darzalex - to bring the myeloma trial (MMY2036) to a halt. ... to Darzalex in 2012 in a deal valued at $1.1bn, ahead of its US approval as a myeloma therapy in 2015.

  • FDA clears first-line use for J&J FDA clears first-line use for J&J

    Johnson &Johnson’s efforts to position Darzalex earlier in the treatment pathway for multiple myeloma have resulted in a coveted FDA approval for first-line use. ... The company’s Janssen unit says Darzalex (daratumumab) has been given the nod for

  • FDA clears first-line use for J&J’s myeloma drug Darzalex FDA clears first-line use for J&J’s myeloma drug Darzalex

    FDA clears first-line use for J&J’ s myeloma drug Darzalex. Frontline approval for Janssen's Darzalex a milestone in march towards blockbuster status. ... Johnson &Johnson’s efforts to position Darzalex earlier in the treatment pathway for multiple

  • J&J pays $140m upfront for cancer-busting virus firm BeneVir J&J pays $140m upfront for cancer-busting virus firm BeneVir

    One exception is J&J’s anti-CD38 drug Darzalex (daratumumab), which is already approved for multiple myeloma but according to the company has potential in other cancers thanks to an

More from news
Approximately 12 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics